Cancer Family
Neuroendocrine Neoplasm
CI-CAN-00000286NENExplore in graph →
Non-malignant698 active trials12 approved drugs34 evidence items
- NCIt
- C3809
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000286NENExplore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05822817 | Comparison of Postoperative Recovery of Sevoflurane and Propofol After Transsphenoidal Surgery | completed | Phase 4 | 252 | Peking Union Medical College HospitalOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT03289741 | A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide | completed | Phase 4 | 51 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 9, 2025 |
| clinicaltrials |
| NCT02842749 | Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China | completed | Phase 4 | 61 | Novartis PharmaceuticalsINDUSTRY | 1 | Feb 10, 2025 | clinicaltrials |
| NCT04524442 | Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients | completed | Phase 4 | 42 | Advanced Accelerator ApplicationsINDUSTRY | 4 | Jan 24, 2025 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT01379898 | Phenoxybenzamine Versus Doxazosin in PCC Patients(PRESCRIPT) | completed | Phase 4 | 134 | University Medical Center GroningenOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT04180176 | Prospective Clinicogenomic Program(PCG) | completed | Phase 4 | 945 | Genentech, Inc.INDUSTRY | 1 | Jan 17, 2024 | clinicaltrials |
| NCT05071703 | Evaluation of TRILACICLIB in Chinese Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC) for Chemotherapy-induced Myelosuppression, Antitumor Effects of Combination Regimens, and Safety in a Real-world Study | completed | Phase 4 | 30 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 6, 2023 | clinicaltrials |
| NCT01344356 | Stereotactic Body Radiotherapy for Head and Neck Tumors | completed | Phase 4 | 19 | Mercy ResearchOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT02075606 | Circulating Tumour Cells in Somatuline Autogel Treated NeuroEndocrine Tumours Patients(CALM-NET) | completed | Phase 4 | 50 | IpsenINDUSTRY | 1 | Jun 7, 2019 | clinicaltrials |
| NCT01371643 | Surgical Debulking of Pituitary Adenomas | completed | Phase 4 | 41 | NYU Langone HealthOTHER | 1 | Aug 29, 2016 | clinicaltrials |
| NCT01317615 | RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation | completed | Phase 4 | 49 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 30, 2016 | clinicaltrials |
| NCT01959711 | Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy | completed | Phase 4 | 65 | Jagiellonian UniversityOTHER | 1 | Oct 10, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Jun 8, 2025source: clinicaltrials